

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
FURTHER BUSINESS UPDATE OF COLLABORATION
ON ANTIBODY-DRUG CONJUGATE

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

Reference is made to the announcement of the Company dated 30 May 2022 in relation to, among other things, the collaboration agreement (the “**Collaboration Agreement**”) entered into with Duality Biologics (Suzhou) Co., Ltd. (“**Duality Biologics**” or “**DualityBio**”) in 2022 for the grant of exclusive rights of its monoclonal antibodies for specific tumor to Duality Biologics to develop the world’s first-in-class antibody-drug conjugate (“**ADC**”).

The board of directors of the Company (the “**Board**”) is pleased to announce that, Beigene, Ltd. (“**BeiGene**”) and Duality Biologics (a collaborator of Nona Biosciences) entered into an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC program for patients with select solid tumors (the “**BeiGene Agreement**”). This program was developed under the Collaboration Agreement.

In 2022, the Company, through Nona Biosciences (formerly known as Harbour BioMed (Suzhou) Co. Ltd, a subsidiary wholly owned by the Company), entered into the Collaboration Agreement with Duality Biologics. Notwithstanding the BeiGene Agreement as disclosed above, the collaboration between Nona Biosciences and Duality Biologics will continue in accordance with the terms of the Collaboration Agreement.

ABOUT DUALITY BIOLOGICS

DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. DualityBio has successfully established a number of next-generation ADC technology platforms with global intellectual property rights. Building upon deep understanding of disease biology and translational capability, DualityBio has advanced four assets into global clinical studies, and developed more than 10 innovative product candidates that are currently in preclinical stage. Additionally, DualityBio is continuing to evolve its novel protein engineering and ADC technology platforms for the next wave of “super ADC” molecules including diverse payload classes, bispecific ADCs and dual-payload ADCs. To learn more about DualityBio, please visit www.dualitybiologics.com.

Cautionary Statement: The Company cannot guarantee that it will be able to successfully develop or ultimately market its products referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 14 July 2023

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.